How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?

被引：0
作者：
Ghosh, Subrata [1 ]
机构：
[1] Hammersmith Hosp, Imperial Coll London, London W12 0NN, England
来源：
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2006年 / 3卷 / 10期
关键词：
adalimumab; anti-tumor necrosis factor; Crohn's disease; therapy;
D O I：
10.1038/ncpgasthep0605
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：540 / 541
页数：2
相关论文
共 5 条
  • [1] Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
    Anderson, PJ
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) : 19 - 22
  • [2] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    Bongartz, T
    Sutton, AJ
    Sweeting, MJ
    Buchan, I
    Matteson, EL
    Montori, V
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19): : 2275 - 2285
  • [3] Clinical pharmacokinetics of TNF antagonists: How do they differ?
    Nestorov, I
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) : 12 - 18
  • [4] An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
    Sandborn, WJ
    Hanauer, S
    Loftus, EV
    Tremaine, WJ
    Kane, S
    Cohen, R
    Hanson, K
    Johnson, T
    Schmitt, D
    Jeche, R
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10) : 1984 - 1989
  • [5] A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
    Targan, SR
    Hanauer, SB
    vanDeventer, SJH
    Mayer, L
    Present, DH
    Braakman, T
    DeWoody, KL
    Schaible, TF
    Rutgeerts, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (15) : 1029 - 1035
1